Transforming growth factor beta secretion from primary breast cancer fibroblasts

Mol Cell Endocrinol. 1995 Apr 28;111(1):1-6. doi: 10.1016/0303-7207(95)03539-j.


Transforming growth factor beta (TGF-beta) is a hormonally regulated growth inhibitor with autocrine and/or paracrine functions in human breast cancer. In vivo, enhanced immunohistochemical staining of extracellular TGF-beta 1 has been detected around stromal fibroblasts in response to the antiestrogen treatment. We have investigated the effects of tamoxifen on the production of TGF-beta by primary human breast fibroblast cultures in serum-free medium. Highly variable levels of mainly latent TGF-beta 1 were detected in conditioned media from both tumor and normal tissue derived fibroblasts. Hydroxy-tamoxifen was shown to increase latent TGF-beta 1 secretion in three of the eight tumor tissue-derived fibroblast cultures. Such effect of hydroxy-tamoxifen was not observed in fibroblast cultures established from normal adjacent breast tissue.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biological Assay
  • Breast Neoplasms / metabolism*
  • Breast Neoplasms / pathology
  • Cell Division
  • Cell Line
  • Culture Media
  • Culture Media, Conditioned
  • Fibroblasts / metabolism
  • Humans
  • Lung
  • Mink
  • Stromal Cells / metabolism
  • Tamoxifen / pharmacology
  • Transforming Growth Factor beta / biosynthesis
  • Transforming Growth Factor beta / metabolism*
  • Tumor Cells, Cultured


  • Culture Media
  • Culture Media, Conditioned
  • Transforming Growth Factor beta
  • Tamoxifen